Acceptable therapeutic approach in relapsed/refractory Mantle Cell Lymphoma...

IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A MULTICENTER OPEN-LABEL PHASE 2 STUDY(független ea)/ The results of a phase 2 clinical trial where chronic graft versus host disease (cGVHD) patients positively respond to ibrutinib...

IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)...

Data that can change the way cancer patients of 65 years and older are treated with anticoagulants, possibly preventing mortality...

Prioritizing therapies in CLL...

DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT...

DASATINIB IN CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM A PHASE 2 TRIAL...

Dr. Vida Lívia, az EHA 2017. évi kongresszusán foglalta össze részünkre a kongresszuson elhangzó újdonságokat a patológusok szemszögéből. Helyszíni interjúnkat a felvételre kattintva érhetik el!...

"Patient assessment: Optimising the stratification of patients with CLL /

How does our understanding of signaling pathways inform treatment decisions? /

Future goals of treatment: Finite duration as a desirable goal(Janssen - Gilead)"...

RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL...

GHSD HD18 study: reducing chemotherapy toxicity in advanced stage Hodgkin lymphoma...

New treatment for Lymphoma patients...

Az ESMO 2017. évi kongresszusán, Madridban Enrique Grande-val készítettünk interjút, aki a veserák kezelésének irányelveit foglalta össze. Tekintsék meg helyszíni interjúnkat!...

Interjú Dr. Szűcs Miklós klinikai főorvos úrral az ESMO 2017. évi Kongresszusán, Madriban...

Interjú Dr. Gálffy Gabriella egyetemi docenssel az ESMO 2017. évi Kongresszusán, Madridban...

Interjú Dr.Ostoros Gyula főorvos úrral az ESMO 2017. évi Kongresszusán, Madridban...

Updates in metastatic colorectal cancer management...

Treatment of young women with breast cancer...

Researching the Potential of Checkpoint Inhibitors in Hepatocellular carcinoma (HCC)...